{"prompt": "['PROTOCOL SYNOPSIS', 'TITLE:', 'A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO', 'EVALUATE THE SAFETY AND TOLERABILITY OF', 'PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS', 'WITH INHIBITORS', 'PROTOCOL NUMBER:', 'MO39129', 'VERSION NUMBER:', '3', 'EUDRACT NUMBER:', '2016-004366-25', 'TEST PRODUCT:', 'Emicizumab (RO5534262)', 'PHASE:', 'Illb', 'INDICATION:', 'Hemophilia A', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'Objectives and Endpoints', 'This study will evaluate the safety and tolerability of emicizumab in patients with congenital hemophilia', 'A who have persistent inhibitors against Factor VIII (FVIII) at enrolment. Specific objectives and', 'corresponding endpoints for the study are outlined below (Table 1).', 'Table 1', 'Objectives and Corresponding Enpoints', 'Objectives', 'Corresponding Endpoints', 'Primary Objective:', 'To evaluate the overall', 'Incidence and severity of all adverse events, including', 'safety and tolerability of', 'thromboembolic events, microangiopathic hemolytic anemia or', 'prophylactic administration', 'thrombotic microangiopathy (TMA) (e.g. hemolytic uremic', 'of emicizumab', 'syndrome), systemic hypersensitivity, anaphylaxis, and', 'anaphylactoid events', 'Changes in physical examination findings, vital signs, and', 'laboratory parameters', 'Secondary Objective:', 'To evaluate the efficacy of', 'To evaluate the efficacy of prophylactic administration of', 'prophylactic administration', 'emicizumab on the basis of the number of bleeds over time', 'of emicizumab', 'To evaluate the HRQoL of patients according to Haem-A-QoL', '(= 18 y) or Haemo-QoL-SF (ages 12-17) scores over time', 'To evaluate the health status of patients according to EQ-5D-5L', 'scores over time', 'To assess patient preference for the emicizumab regimen', 'compared with the previous regimen used', 'Immunogenicity Objective:', 'To evaluate the immuno-', 'To assess the incidence and clinical significance of anti-', 'genicity of emicizumab', 'emicizumab antibodies', 'Emicizumab - F. Hoffmann-La Roche Ltd', '77 / Protocol MO39129, Version 3']['Objectives', 'Corresponding Endpoints', 'PK Objective:', 'To obtain emicizumab PK', 'To obtain PK data for emicizumab at defined timepoints', 'data', 'EQ-5D-5L=EuroQoL Five-Dimension-Five Levels Questionnaire; Haem-A-QoL=Hemophilia Adult', 'Quality of Life Questionnaire; Haemo-QoL-SF=Hemophilia Quality of Life Short Form; HRQoL=Health-', 'Related Quality of Life; PK=pharmacokinetic; TMA=thrombotic microangiopathy', 'Study Design', 'Description of Study', 'This single-arm, multicenter, open label, Phase IIIb clinical study will enroll patients aged 12 years or', 'older with congenital hemophilia A who have persistent inhibitors against FVIII at enrollment.', 'Approximately 200 patients with inhibitors will be enrolled globally. Patients will receive prophylactic', 'emicizumab at 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week', 'subcutaneously for the remainder of the 2-year treatment period (Figure 1).', 'Figure 1', 'Study Design', 'Patients with congenital', 'hemophilia A of any', 'Initial dose:', 'Maintenance dose:', 'severity who have', 'Emicizumab', 'Emicizumab', 'inhibitors against FVIII', '3 mg/kg/wk SC', '1.5 mg/kg/wk SC', '(n=200)', '4 weeks', '2 years', 'FVIII=Factor VIII; SC=subcutaneous', 'The primary objective of this study is to evaluate the overall safety and tolerability of prophylactic', 'administration of emicizumab in patients with congenital hemophilia A who have persistent inhibitors', 'against FVIII at enrollment. In order to achieve this objective, all adverse events, including adverse', 'events of special interest, will be captured on an ongoing basis, as they occur during the study.', 'Physical examinations, vital signs, and laboratory values will be assessed as per the Schedule of', 'Activities (Appendix 1', 'Schedule of Activities', ').', 'The secondary objective of this study is to evaluate the efficacy of prophylactic administration of', 'emicizumab. As part of this objective, the number of bleeds over time will be recorded for all of the', 'enrolled patients.', 'The final analysis will be conducted when all patients have completed 2 years of treatment or have', 'withdrawn, whichever occurs sooner. Patients, or their legally authorized representative, will be asked', 'to report bleed information on an electronic patient-reported outcome (ePRO) device where possible,', 'including site of bleed, type of bleed, time of each individual bleed (day, start and stop time), and', 'treatment for bleed. Health-Related Quality of Life (HRQoL) will be assessed and the EuroQoL Five-', 'Dimension-Five Levels Questionnaire (EQ-5D-5L) will be completed prior to the first emicizumab', 'administration (Week 1), at the Month 3, 6, 12, and 18 assessments, and at study completion as', 'outlined in the Schedule of Activities (Appendix 1', 'Schedule of Activities', '). Additional secondary endpoints include assessing patient preference for the emicizumab regimen', 'compared with the previous regimen using a questionnaire (EmiPref).', 'Immunogenicity will be monitored by incidence and clinical significance of antibodies to emicizumab.', 'In addition, pharmacokinetic (PK) data for emicizumab will be obtained at defined timepoints as per', 'Emicizumab - F. Hoffmann-La Roche Ltd', '78 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}